Generate text that refutes this claim: Dominance of generic drugs will reduce reinvestment and innovation in donating countries  The production of high quality generic drugs endangers pharmaceutical progress. In order to export high quality generic drugs, some countries have suggested allowing generic drug manufacturers access to patented drugs. In Canada, amendments to Canada’s Access to Medicine Regime (CAMR) would have forced pharmaceutical research companies to give up their patents [1] . This is problematic however as research based companies invest a large proportion of their profits back in to the industry. The requirements proposed for some Western countries for obligatory quantities of generic drugs to be given to Africa have been accused to removing any incentive to invest in research to combat disease [2] .  [1] Taylor,D. ‘Generic-drug “solution” for Africa not needed’  [2] ibid
disease healthcare international africa censorship ip house would produce high
Some countries, such as India and Thailand, have specialised in producing generic drugs. These states provide the majority of generic drugs to Africa. This removes the burden of other countries to supply Africa with their own drugs whilst potentially damaging their own research companies. India has managed to create a very profitable industry based around cheap generic drugs which it mainly exports to the African continent [1] , decreasing the necessity of other states to contribute vast resources.  Providing generics to Africa will not damage development by the big pharmaceutical companies as at the moment these countries cannot afford the drugs so are not a market. The drugs are researched on the assumption that they will be sold in the developed world. What matters therefore is to ensure that generics for Africa don’t get sold back to the developed world undercutting patented drugs.  [1] Kumar,S. ‘India, Africa’s Pharma’